Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. uri icon

authors

  • Poveda, Andrés
  • Friedlander, Michael
  • Baldoni, Alessandra
  • Park-Simon, Tjoung-Won
  • Tamura, Kenji
  • Sonke, Gabe S
  • Lisyanskaya, Alla
  • Kim, Jae-Hoon
  • Filho, Elias Abdo
  • Milenkova, Tsveta
  • Lowe, Elizabeth S
  • Floquet, Anne
  • Rowe, Phil
  • Vergote, Ignace
  • Pujade-Lauraine, Eric
  • Ledermann, Jonathan A
  • Asher, Rebecca
  • Penson, Richard T
  • Oza, Amit M
  • Korach, Jacob
  • Huzarski, Tomasz
  • Pignata, Sandro

publication date

  • January 1, 2021